Biomea Fusion (NASDAQ:BMEA) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219. This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns. The regulator is worried about possible drug-induced hepatotoxicity. This comes after the trials may have led to liver enzyme elevations. BMF-219 is Biomea Fusion’s candidate to treat type 2 and type 1 diabetes. The company says it will continue to collec ...